Nasdaq · Healthcare
ARVINAS, INC. (ARVN)
As-reported financials and recent SEC filings for ARVINAS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$262.6M
Net income
$-80.8M
Net margin
-30.8%
Diluted EPS
$-1.14
ROE
-18.6%
P/E (TTM)
—
Market cap
$516.2M
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $262.6M | $263.4M | $78.5M | $131.4M | $53.6M |
| Gross profit | — | — | — | — | — |
| Operating income | $-118.5M | $-250.2M | $-401.5M | $-263.2M | $-188.4M |
| Net income | $-80.8M | $-198.9M | $-367.3M | $-282.5M | $-191.0M |
| Diluted EPS | $-1.14 | $-2.77 | $-6.62 | $-5.31 | $-3.82 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →8-K2026-06-25
View on EDGAR →42026-06-24
View on EDGAR →Go deeper on ARVN
Search ARVINAS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.